Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice”

Okamura, Keisuke; Yano, Yuiko; Takamiya, Yosuke; Shirai, Kohji; Urata, Hidenori

doi:10.1080/10641963.2019.1693586

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concurrently, RAS blockers attenuate the potassium depletion induced by thiazide diuretics, thereby minimizing the likelihood of hypokalemia ( 149 ). An open-label study found that a combination drug of an angiotension receptor blocker (ARB) olmesartan and a calcium channel blocker (CCB) azelnidipine was effective in reducing both systolic and diastolic blood pressure in patients with resistant hypertension in both office and at home ( 150 ). The study also noted that the combination therapy was generally well-tolerated and did not result in any significant adverse events.…”

Section: Treatment Optionsmentioning

confidence: 99%

When blood pressure refuses to budge: exploring the complexity of resistant hypertension

Champaneria,

Patel,

Oroszi

2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Resistant hypertension, defined as blood pressure that remains above goal despite using three or more antihypertensive medications, including a diuretic, affects a significant proportion of the hypertensive population and is associated with increased cardiovascular morbidity and mortality. Despite the availability of a wide range of pharmacological therapies, achieving optimal blood pressure control in patients with resistant hypertension remains a significant challenge. However, recent advances in the field have identified several promising treatment options, including spironolactone, mineralocorticoid receptor antagonists, and renal denervation. In addition, personalized management approaches based on genetic and other biomarkers may offer new opportunities to tailor therapy and improve outcomes. This review aims to provide an overview of the current state of knowledge regarding managing resistant hypertension, including the epidemiology, pathophysiology, and clinical implications of the condition, as well as the latest developments in therapeutic strategies and future prospects.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%